Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has been under a strong bear grip, hence the stock is down -4.31% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.11% in the past 1 week. The stock has risen by 1.39% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.77% in the past 4 weeks.
The company shares have dropped -28.40% from its 1 Year high price. On Aug 10, 2015, the shares registered one year high at $143.45 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $89.04 and the 200 Day Moving Average price is recorded at $90.26.
The stock has recorded a 20-day Moving Average of 1.7% and the 50-Day Moving Average is 2.04%.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): On Fridays trading session , Opening price of the stock was $90.08 with an intraday high of $90.43. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $88.65. However, the stock managed to close at $88.96, a loss of 1.21% for the day. On the previous day, the stock had closed at $90.05. The total traded volume of the day was 1,794,278 shares.
In an insider trading activity, The Securities and Exchange Commission has divulged that Boger Joshua S, director of Vertex Pharmaceuticals Inc / Ma, had unloaded 5,140 shares at an average price of $88.33 in a transaction dated on July 6, 2016. The total value of the transaction was worth $454,016.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.